The professional cycling world received disappointing news this month with the announcement that Kern Pharma, the Spanish pharmaceutical company that has served as title sponsor of Equipo Kern Pharma since the team’s founding in 2020, will step away from the sport at the end of the 2026 season. The departure leaves the ProTeam-level squad searching for a new primary sponsor to ensure its survival beyond this year.
Six Years of Building a Team
Kern Pharma’s involvement in cycling began in 2020 when the company backed the creation of a new second-tier Spanish team designed to develop young talent. Over six seasons, the team has served as a valuable stepping stone for Spanish riders looking to break into the WorldTour. Several riders who developed at Kern Pharma have gone on to secure contracts with top-tier teams, validating the team’s approach to talent development.
The team earned invitations to several prestigious races, including stages of the Vuelta a España, giving its young riders exposure to the highest level of competition. For Spanish cycling, which has seen a decline in the number of domestic professional teams in recent years, Kern Pharma’s presence provided crucial opportunities for emerging riders who might otherwise have struggled to find professional team placements.
Why Sponsors Leave
While the specific reasons behind Kern Pharma’s departure have not been publicly detailed, the decision reflects challenges that are common across cycling sponsorship. Companies regularly reassess their marketing strategies, and the return on investment from cycling sponsorship can be difficult to quantify compared to digital advertising and other modern marketing channels. Pharmaceutical companies in particular face regulatory constraints on sports marketing in some markets.
The economics of running a professional cycling team remain challenging even at the second tier. Annual budgets for ProTeams typically range from €3 million to €8 million, covering rider salaries, staff costs, equipment, travel, and logistics for a full season of racing across Europe and beyond. Generating sufficient commercial value to justify this investment requires sustained media exposure and results that keep the brand visible.
The Broader Impact
Kern Pharma’s exit comes at a time of significant financial stratification in professional cycling. While top-tier teams are securing record-breaking sponsorship deals, as evidenced by the reported €100 million investment heading to Ineos Grenadiers, teams at the ProTeam and Continental levels increasingly struggle to attract and retain sponsors. This widening gap raises concerns about the health of cycling’s developmental pipeline.
Without a strong layer of second-tier teams to develop talent, the sport risks concentrating resources among a shrinking number of wealthy organizations. This would limit opportunities for young riders, reduce the diversity of the professional peloton, and potentially weaken the competitive depth that makes cycling races compelling. The loss of each developmental team has cascading effects that extend far beyond the riders and staff directly affected.
The team’s management is actively seeking replacement sponsorship, and the quality of the riders and staff on the roster makes the squad an attractive proposition for potential backers. Spanish cycling has a deep tradition and passionate fanbase, factors that should appeal to companies looking for sports marketing opportunities in the Iberian market. The coming months will determine whether a new partner can be found in time to preserve the team for 2027 and beyond.
For now, the riders and staff of Equipo Kern Pharma face a season of uncertainty as they race with one eye on the road and another on the future of their team. It is a situation all too familiar in professional cycling, where the gap between sporting success and financial stability remains one of the sport’s most persistent challenges.
